^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Endometrial Cancer

    Related cancers:
    18h
    Ph 2 Elacestrant in ER Positive Uterine Sarcomas (clinicaltrials.gov)
    P2, N=30, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor)
    |
    Orserdu (elacestrant)
    22h
    Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, Regor Pharmaceuticals Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    22h
    Tirzepatide in Obesity-Driven Endometrial Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Initiation date: Feb 2026 --> Jul 2026
    Trial initiation date
    |
    IGF1 (Insulin-like growth factor 1)
    1d
    EZHiSWITCH: Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. (clinicaltrials.gov)
    P2, N=900, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    Trial initiation date
    |
    ARID1A (AT-rich interaction domain 1A) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    Ezharmia (valemetostat)
    1d
    Clinical significance of MIF in predicting lymph node metastasis and immune-inflammatory characteristics in endometrial cancer: a retrospective study of 361 patients. (PubMed, Am J Transl Res)
    Tumor MIF expression is an independent predictor of LNM in EC. Incorporation of MIF into a clinically grounded prediction model may enhance preoperative risk stratification of EC.
    Retrospective data • Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated) • MIF (Macrophage Migration Inhibitory Factor)
    1d
    Endometrial Neuroendocrine Carcinoma With Widespread Metastases: Diagnostic and Therapeutic Challenges in a Rare Malignancy. (PubMed, Cureus)
    She underwent urgent T1 laminectomy with C5-T3 fusion, followed by systemic therapy with carboplatin/paclitaxel plus pembrolizumab, and later transitioned to carboplatin/etoposide. Histopathology confirmed small-cell NEC with squamous differentiation; expert review favored a poorly differentiated/dedifferentiated endometrial carcinoma with neuroendocrine and squamoid features. This case illustrates an atypical initial presentation with neurologic deficits from spinal metastases, emphasizing the need for prompt recognition and multidisciplinary management.
    Journal • PD(L)-1 Biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • etoposide IV
    1d
    Integrated multi-omics and machine learning highlight PTM-related genes as potential biomarkers in endometrial cancer. (PubMed, Transl Oncol)
    This study provides valuable insights into the role of PTMs in endometrial cancer, identifying potential biomarkers for diagnosis and treatment.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    1d
    MLH1 promoter methylation-induced dMMR/MSS in endometrial cancer: case report. (PubMed, Discov Oncol)
    In conclusion, for endometrial cancer patients exhibiting dMMR by IHC but MSS by MSI testing, MLH1 promoter methylation testing becomes even more critical. This not only aids in screening for Lynch syndrome, enabling pathologists to make a more precise diagnosis, but also provides important guidance for clinical treatment decisions.
    Journal • IO biomarker • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1)
    |
    MSI-H/dMMR
    3d
    SENGA: Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer (clinicaltrials.gov)
    P3, N=10, Completed, UMC Utrecht | Not yet recruiting --> Completed
    Trial completion
    3d
    Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial. (PubMed, Gynecol Oncol)
    Cadonilimab combined with chemotherapy demonstrated clinically meaningful activity and manageable safety as first-line treatment for advanced or recurrent EC, supporting further investigation, particularly in molecularly defined populations.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Kaitanni (cadonilimab)
    3d
    Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer. (PubMed, Gynecol Oncol)
    Selective molecular profiling of newly diagnosed stage III-IVA endometrial cancers using MMR and p53 IHC with reflex to NGS for p53-abnormal tumors improves testing efficiency and reduces unnecessary NGS compared with universal upfront NGS testing.
    Clinical • Journal • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • POLE (DNA Polymerase Epsilon)
    |
    TP53 mutation • POLE mutation
    3d
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=194, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)